Drug Trial Radar · NCT03828773
PTX3-targeted Antifungal Prophylaxis
Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
Feb 11, 2019
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Bochud Pierre-YvesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Swiss National Science Foundation
- First posted
- Feb 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.
Conditions
- Candidiasis
- Fungal Infection
- Acute Myeloid Leukemia
- Genetic Predisposition
- Aspergillosis
Interventions
PosaconazoleDrug
Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
FluconazoleDrug
Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence of proven and probable invasive mold infection (IMI)Time frame: Day 180
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
AZ Sint-Jan Hospital
Bruges, Belgium · Recruiting
University Hospital Leuven (UZ Leuven)
Leuven, Belgium · Recruiting
Ghent University Hospital
Ghent, Belgium, Belgium · Terminated
Henri Mondor Hospital
Créteil, Île-de-France Region, France · Recruiting
Cantonal Hospital Aarau
Aarau, Aarau, Switzerland · Recruiting
University Hospital Basel
Basel, Basel, Switzerland · Recruiting
Cantonal Hospital HFR
Fribourg, Canton of Fribourg, Switzerland · Recruiting
University Hospital of Geneva (HUG)
Geneva, Canton of Geneva, Switzerland · Recruiting
University Hospital of Lausanne / Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Canton of Vaud, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.